

Nephros, Inc.

Fact Sheet

N E P H

S Y M B O L

OTCQB

NEPH Uplisting onto Nasdaq – Date To Be Announced

NEPHROS

QUICK REFERENCE

Nephros, Inc.

Trading Symbol: NEPH

Outstanding Shares: **7,387,930**

Website: **www.NEPHROS.com**

BUSINESS SUMMARY

Nephros is a commercial stage company that develops and sells high performance water purification products to the medical device and commercial markets. Nephros ultrafilters are used in hospitals and medical clinics for added protection in retaining bacteria (e.g., Legionella, Pseudomonas) and viruses from water, providing barriers that assist in improving infection control in showers, sinks, and ice machines. Additionally, Nephros ultrafilters are used by dialysis centers for assisting in the added removal of endotoxins and other biological contaminants from the water and bicarbonate concentrate supplied to hemodialysis machines and patients.

Nephros filters, including AETHER™ brand filters, improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. Nephros and AETHER™ products are used in the health care, food service, hospitality, and convenience store markets.

Q2 2019 Financial Results Conference Call

- **August 7, 2019 at 4:30 PM ET**
- Dial in: 1-866-652-5200
- International callers: +1-412-317-6060.
- Please ask to be joined into the Nephros conference call

- A replay of the call can be accessed until Aug 14, 2019 at 1-877-344-7529 or 1-412-317-0088 for international callers and entering replay access code: 10134030

- An audio archive of the call will be available shortly after the call on the Nephros investor relations page at <https://www.nephros.com/investor-relations>

CONTACT INFORMATION

US Headquarters
380 Lackawanna Place
South Orange, NJ 07079

Investor Relations Contact
Andrew Barwicki
516-662-9461
andrew@barwicki.com

Recent Press Releases *(Headlines and Excerpts)*

Nephros Announces Second Quarter 2019 Financial Results Conference Call and Record Revenue of Over \$1 Million in July

July 30, 2019 -- Nephros, Inc. announced that it will publish its second quarter 2019 financial results on Wednesday, August 7, 2019 and will host a conference call that same day at 4:30 PM ET, during which management will discuss the company's financial results and provide a general business overview. The company also announced that it has surpassed \$1 million revenue in one month for the first time, during the month of July.

Nephros Announces Temporary Ticker Symbol Following Reverse Stock Split ***Common Stock Will Trade Under Ticker "NEPHD" for 20 Trading Days***

July 10, 2019 -- Nephros, Inc. announced that its common stock will trade on the OTCQB under the ticker "NEPHD" for the next 20 trading days. This temporary change in ticker symbol is a result of Nephros' previously announced one-for-nine reverse split of its common stock, which became effective following the close of business on July 9, 2019. After the expiration of this 20-day period, the ticker will revert back to "NEPH." The new CUSIP number for Nephros' common stock is 640671400.

Nephros Announces Preliminary Financial Results for Second Quarter 2019 and Reverse Stock Split ***Anticipates \$2.3 Million Net Revenue; 70% Growth Over Prior Year*** ***Reiterates Full-Year 2019 Revenue Guidance***

July 09, 2019 -- Nephros, Inc. announced preliminary financial results for the quarter ended June 30, 2019. The Company also announced that its Board of Directors has approved a one-for-nine reverse stock split of its common stock that will be effective at 5:30pm Eastern Daylight Time today.

Net revenues are expected to be approximately \$2.3 million, an increase of 70% compared to the quarter ended June 30, 2018. Product revenues increased 90% over the same period.

"We are pleased with the preliminary results of the second quarter of 2019 and reiterate our previous guidance for full-year revenue of \$8.5 to \$9.5 million in 2019," said Daron Evans, President and CEO of Nephros. "The reverse stock split is being effected as a part of our previously stated plan to uplist to a national stock exchange. With our consistent growth trajectory and additional growth initiatives, we believe that the Company's value may be better reflected by having the Company's stock listed on a national stock exchange and we continue to work on our plan to obtain that listing."

The Company expects that, beginning with the opening of trading on July 10, 2019, the Company's common stock will trade on the OTCQB Market on a split-adjusted basis under the new CUSIP number 640671400. The Company's common stock will continue to trade under the symbol "NEPH."

Nephros Announces \$2 Million Private Placement

May 16, 2019 -- Nephros, Inc. that it has completed a private placement in which it sold approximately 4.4 million shares of common stock at a purchase price of \$0.45 per share, resulting in total gross proceeds to the company of \$2 million. The private placement was led by the Pessin and Farwell families.

"We appreciate the ongoing support of our investors," said Daron Evans, President and CEO of Nephros. "Our existing investors' interest enabled us to opportunistically solidify our balance sheet as we prepare to up-list to a national securities exchange and to finalize the development of our water pathogen diagnostic product."

Nephros Appoints Tom Gwydir to its Board of Directors

May 01, 2019 -- Nephros, Inc. announced the appointment of Tom Gwydir to its Board of Directors.

Mr. Gwydir is currently Chief Information Officer (CIO) at the London Stock Exchange. Prior positions have included CIO and Chief Technology Officer at MSCI, Managing Director of Platform Services at UBS, and Vice President of Technology at Asurion. He has also held senior roles at Wells Fargo, Merrill Lynch, Dun & Bradstreet, and Magna Software. He received his B.S. in Industrial Engineering from Columbia University.

This Company Fact Sheet is distributed by Andrew Barwicki, Investor Relations. Contact Info: 516-662-9461 / andrew@barwicki.com
The information contained is neither an offer to sell nor a solicitation of an offer to buy any securities mentioned. This Company Fact Sheet is an information publication and is considered investor relations & financial public relations material. All information regarding Nephros Inc is compiled from SEC Filings (U.S. Securities and Exchange Commission), press releases, conference calls, shareholder meetings, investment conferences, analyst reports, and/or senior management interviews. This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.

Standard Mail
U.S. Postage Paid
Garden City, NY
Permit No. 431

Nephros, Inc.
Trading Symbol: NEPH
www.NEPHROS.COM

Barwick Investor Relations • 30 Wall Street, 8 FL • New York, NY 10005

Deliver to: